To investigate whether there is an epidemiological correlation between Borna disease virus (BDV) infection and human neuropsychiatric diseases, we established a reverse-type sandwich enzyme-linked immunosorbent assay (RS-ELISA) for detecting specific antibodies to BDV. In this assay, microplate wells were coated dispersely with BDV p40 antigen, followed by the addition of test samples at a low dilution and then the biotinylated p40. A preformed complex of streptavidin and horseradish peroxidase-conjugated biotin and an enzyme substrate were used to measure the captured biotinylated p40. Theoretically, RS-ELISA should specifically detect anti-BDV antibodies without nonspecific signals; such signals possibly occur in conventional serological assays. Additionally, the RS-ELISA could be applied under the same protocols to test samples from a variety of animals. By using anti-BDV rat and rabbit sera, the assay was standardized so that it had high specificity and sensitivity. When we used the RS-ELISA to determine the presence of anti-BDV antibodies in plasma from 70 patients with chronic schizophrenia as well as 40 healthy individuals in the Tokyo area of Japan, no plasma sample was found to possess specific antibodies to BDV p40, indicating no association between BDV infection and the disease in our testing population. A negative reaction was also shown for the sera that had previously been judged to be seropositive for BDV by an immunofluorescence or immunoblot test. These findings suggested that false-positive cases of infection due to nonspecific reactions may be included in previous seroepidemiological information with regard to BDV.
Borna disease, a progressive immune-mediated neurological disease characterized by behavioral disturbances and movement disorders, is caused by an enveloped, nonsegmented, negative-stranded RNA virus [Borna disease virus (BDV)] (7, 8, 22, 26, 28) . Although originally restricted to horses and sheep in southeastern Germany, natural infections with BDV have also been confirmed in rabbits, cats, cattle, and ostriches in other geographic areas (22) . BDV-induced neuropsychiatric manifestations were also observed in other animal species including rodents and primates through experimental infections (22) . The wide host range of BDV infections in animals and disease signs that resemble certain types of affective disorders in humans (27) have raised a possible association between BDV or BDV-like agents and human neuropsychiatric diseases.
On the basis of this possibility, several researchers have done seroepidemiological studies with humans (1, 2, 4, 10, 17, (23) (24) (25) 29) . Most findings provided evidence of BDV infections in humans, showing a significantly higher percentage of seropositive individuals among neuropsychiatric patients than healthy subjects. Similarly, an epidemiological approach to the detection of BDV RNA in peripheral blood mononuclear cells (PBMCs) by reverse transcriptase PCR has also suggested a correlation between BDV and neuropsychiatric diseases (5, 14, 25) . Furthermore, BDV-like viruses were isolated from PBMCs (3), and BDV antigen and RNA were detected in autopsied brain samples from psychiatric patients (9) . However, there is no direct evidence that BDV is the causative factor of human diseases.
Unlike infections with lytically replicating viruses, very low antibody titers against BDV have previously been found in human sera. Thus, to detect anti-BDV antibody, assays with high specificities are required, particularly when sera from neuropsychiatric patients are used at a low dilution, because such sera may contain some autoantibodies or unknown factors causing nonspecific reactions (11, 16 ).
In the study described here, we developed a reverse-type sandwich enzyme-linked immunosorbent assay (RS-ELISA) for the detection of anti-BDV antibodies using bacteriumexpressed recombinant p40 protein as a target antigen. Theoretically, major nonspecific signals should be eliminated more in this assay than in other, traditional assays such as immunofluorescence and immunoblot assay and indirect ELISAs. By the RS-ELISA, we demonstrated the possibility that some positive signals for human samples from neuropsychiatric patients by traditional assays are due to nonspecific reactions that occur more frequently in neuropsychiatric patients.
MATERIALS AND METHODS
Subjects. We used plasma specimens from 70 unselected inpatients with chronic schizophrenia at the Tokyo Metropolitan Matsuzawa Hospital and 40 healthy medical staff members working there. We also used six additional human serum specimens which had previously been assessed in other laboratories to be seropositive for BDV by an immunofluorescence or immunoblot test. All serum and plasma samples were stored at Ϫ20°C until use.
Anti-BDV antibody. Serum from rats infected with BDV and normal rat serum were kindly supplied by W. I. Lipkin (University of California, Irvine). Sera from BDV-infected rabbits and mouse monoclonal antibodies to p40 were kind gifts from L. Stitz and S. Herzog through R. Rott (Justus-Liebig-Universität, Giessen, Germany).
Generation of recombinant protein. The full-length cDNA encoding p40 was cloned into the prokaryotic expression vector for the production of recombinant p40. To construct this vector (pGEX.p40.Ger), we amplified the p40 gene by PCR with the primers p40-0(I/BamHI) (5Ј-GTGGGATCCCCATGCCACCGA AGAGACGCCTGG-3Ј) and p40-1112(T/XhoI) (5Ј-CCGCTCGAGCTAGTTT AGACCAGTCACACCTAT-3Ј) from pcDNA2.1 (20) (kind gift from J. A. Richt, Justus-Liebig-Universität). PCR was performed with Taq polymerase according to the manufacturer's protocol (Perkin-Elmer Cetus, Branchburg, N.J.). The PCR product was cloned into the pCRII TA cloning vector (Invitrogen, San Diego, Calif.), and the resulting plasmid was digested with BamHI and XhoI. The digested fragment containing p40 cDNA was inserted into pGEX-5X-3 (Pharmacia, Uppsala, Sweden), which produced the fusion protein with glutathione S-transferase (GST) and recombinant p40 in Escherichia coli. The fusion protein was purified by binding on glutathione-Sepharose 4B (Pharmacia), and the p40 was then released by blood clotting factor Xa, which cleaved between GST and p40 of the fusion protein, according to the manufacturer's protocol. The final p40 solution was used as an antigen in the ELISA to detect anti-BDV antibodies. Purification was assessed by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) with molecular weight markers, and antigenicity was confirmed by immunoblot assay with anti-p40 monoclonal antibodies and virusinfected rat serum.
GST alone was also purified from the culture of vector plasmid (pGEX-5X-3)-transformed E. coli by binding on glutathione-Sepharose 4B and sham cleavage with factor Xa under the same conditions described above. The final solution, in which factor Xa and a small amount of bacterial proteins contaminated through the purification procedures were included, was used as a control antigen for ELISA.
Biotinylation was performed as described by Nerurkar et al. (19) . Briefly, 1 mg of the p40 solution per ml in 0.1 M carbonate buffer (pH 9.6) was mixed with 1/10 volume of N-hydroxysuccinimidobiotin (1 mg/ml in dimethylformamide) for 4 h at room temperature. Biotinylated p40 was separated from unbound biotin through a Sephadex G-50 column (Pharmacia).
Indirect ELISA. A microplate (MaxiSoap; Nunc, Roskilde, Denmark) was coated with 500 ng of recombinant p40 per ml in 100 l of borate buffer (100 mM boric acid, 50 mM sodium borate, 75 mM sodium chloride [pH 8.4]) for 3 h at 37°C. The plate was washed three times with washing buffer (0.05% Tween 20 in phosphate-buffered saline [PBST; pH 7.2]) and was incubated with blocking buffer containing a commercially available skim milk-based reagent (4% Block Ace [Dainihon Seiyaku, Suita, Japan] in phosphate-buffered saline [PBS]) at 200 l per well overnight at 4°C. Test plasma or serum diluted with blocking buffer was then added to the well in 100-l aliquots, and the plate was incubated for 2 h at 37°C. After three washings of the plate, 100 l of horseradish peroxidase (HRP)-conjugated goat anti-human immunoglobulin G (IgG) (Cappel, Durham, N.C.) diluted 1:5,000 in blocking buffer was added to each well, and the plate was incubated for 1 h at 37°C. The plate was then washed eight times, and 100 l of substrate solution (100 mM acetate/citrate buffer [pH 6.0], 100 g of 3,3Ј,5,5Ј-tetramethylbenzidine per ml, 0.45% H 2 O 2 ) was added to each well. After incubation in the dark for 30 min at room temperature, the enzyme reaction was stopped by the addition of 100 l of 1 N H 2 SO 4 . The A 450 minus the A 650 was determined for each well with a microplate reader (Organon Teknika, Turnhout, Belgium). As a negative control reaction, the wells with control antigen were used for calibration. All procedures were identical to those described above with p40 antigen, except that coating was with the control antigen instead of the p40 antigen.
RS-ELISA. Microplate wells were coated with 200 ng of p40 antigen per ml in the presence of 0.5 M NaCl and 20 g of bovine serum albumin (BSA; Sigma, St. Louis, Mo.) per ml in 100 l of 50 mM carbonate buffer (pH 9.6) for 3 h at 37°C. The plate was washed three times with washing buffer and was incubated with blocking buffer at 200 l per well for 1 h at 37°C. A total of 100 l of the test plasma or serum diluted with PBST containing 10% fetal calf serum (PBST/F) was added to each well, and the plate was incubated overnight at 4°C. After three washings of the plate, 50 g of the E. coli lysate per ml, which consisted of the supernatant that was obtained by ultrasonication and then centrifugation (10,000 ϫ g for 10 min in a microcentrifuge tube) of the E. coli suspension in PBS with 1% Triton X-100, was added to the well along with 100 l of PBST/F. The plate was then incubated for 3 h at 37°C. The plate was then washed three times, 2 g of biotinylated p40 per ml in 100 l of PBST/F was added to each well, and the plate was incubated for 1 h at room temperature. After three washings, the plate was reacted with the preformed complex of streptavidin and HRP-conjugated biotin (ABC kit; Vector Laboratory, Burlingame, Calif.) at 100 l per well for 1 h at 37°C. After eight washings of the plate, substrate solution (100 l) was then added to the well and the plate was incubated in the dark for 30 min at room temperature. The enzyme reaction was stopped by the addition of 100 l of 1 N H 2 SO 4 , and the A 450 minus the A 650 was determined for each well. As a negative control reaction, control antigen instead of p40 antigen was coated to the wells, followed by the same other procedures with p40 antigen.
RESULTS
Preparation of recombinant BDV p40 for ELISAs. BDV p40 was highly expressed in a fusion form with bacterial GST in E. coli. p40 alone was purified from the fusion protein by cleavage with factor Xa. SDS-PAGE revealed the presence in the final p40 solution of a major amount of protein with a molecular size of 40 kDa and a minor amount of several proteins with various molecular sizes (data not shown). By immunoblotting, BDV-infected rat serum and anti-p40 monoclonal antibodies reacted with the 40-kDa protein but not with other proteins. Thus, several bacterial proteins were contaminants but were a minor population in the p40 solution. The purity of p40 was 95%, as estimated from the staining of the SDS-polyacrylamide gel. We speculated that when this p40 solution was used as an antigen in the ELISA, the bacterial proteins contaminating this antigen give a high background reaction due to the possible presence of anti-bacterial antibodies in human sera. Thus, we prepared a control antigen for the ELISA. This preparation contained factor Xa as well as bacterial proteins, similar to the p40 antigen solution. We diluted the control antigen in the same fashion that we diluted p40 coating antigen and used it in control wells.
Establishment of an indirect ELISA to detect antibodies to BDV p40. To establish an indirect ELISA for the detection of anti-BDV antibodies in human sera, we first had to determine the optimal concentration of the p40 antigen. However, authentic positive and negative human reference sera for BDV antibodies, which were required for standardization of the assay, were lacking. Instead, when we examined the optimal concentration of the p40 antigen using BDV-infected rat serum and normal rat serum as well as HRP-conjugated second antibody (anti-rat IgG), 50 ng of the antigen per well was optimal, resulting in a linear response. For this preparation, our stock solution of p40 antigen (1.5 mg/ml) was diluted 1:3,000 with coating buffer. To determine the background reaction, we used control antigens at the same dilution (1:3,000), which should provide concentrations of factor Xa and contaminated bacterial proteins similar to those in the wells with the p40 antigen. The antibody to p40 should be detected by evaluating the difference between absorbance values for wells containing p40 and those containing control antigen.
We tested BDV-infected rabbit sera for anti-p40 antibodies. Considerably high background signals from nonspecific reactions were observed in control wells with samples at low dilutions, indicating that nonspecific adhesion of antibodies to the well surface occurred in the absence of p40 antigen. This was not improved under other blocking conditions such as with the use of BSA. Marked differences in optical densities (ODs) between p40-and control antigen-coated wells were observed for only one serum sample (from rabbit 2), whereas little or no differences were found for the other wells (Table 1) . These findings indicated a low sensitivity of this assay for rabbit sera or low levels of specific antibodies induced by BDV infections in rabbits.
Detection of antibodies to BDV p40 in human specimens by indirect ELISA. We investigated the presence of anti-BDV antibodies in plasma from 70 chronic schizophrenia patients and 40 healthy individuals. All plasma samples were diluted to 1:200 and were reacted in duplicate with either p40 or control antigen. The differences in ODs between the p40-and control antigen-coated wells were calculated, and each datum was plotted in Fig. 1 . For some specimens considerably high background signals were shown in the control wells. For example, background values in control antigen-coated wells were larger than differences in values between p40-and control antigen-coated wells for 35 samples from 70 patients and 37 samples from 40 healthy individuals (Fig. 1) . Thus, we considered whether the test samples had different contents of nonspecific factors. Nonetheless, the plotting profiles for the patients and the healthy individuals were clearly different; the ODs for the former were higher than those for the latter, suggesting a possible association between BDV and schizophrenia. However, we could not determine a cutoff value for judging a sample as BDV seropositive or seronegative in the absence of authentic positive or negative human reference sera.
Establishment of an RS-ELISA to detect antibodies to BDV p40. Although our findings by indirect ELISA indicated a possible association between BDV and neuropsychiatric disease, we speculated that nonspecific reactions may affect the results. Thus, we established an RS-ELISA with high reaction specificity to detect anti-BDV antibody (Fig. 2) .
In the RS-ELISA, if both of the binding sites of an antibody (IgG) molecule combine with the solid-phase antigens, the antibody no longer reacts with the labeled antigen in the liquid phase, resulting in a negative reaction. Therefore, the antigen density on the solid phase is crucial in eliciting a positive reaction with a high sensitivity. The antigen proteins must be separated from each other by a sufficient distance to permit a All samples were gifts from other laboratories. Only human sample 6 was plasma; the others were sera.
b The assay was done as described previously (24) . Titers are expressed as the highest dilution showing positive signals, as obtained previously in other laboratories.
c Titers are expressed as the highest dilution showing a difference in OD of 0.1 between p40 antigen-and control antigen-coated wells. Samples from rabbits 1 and 4 showed high background signals (OD of more than 0.1 in control wells at dilutions up to 1:80 for rabbit 1 and 1:160 for rabbit 4).
d Titers are expressed as the highest dilution showing a difference in OD of 0.05 between p40 antigen-and control antigen-coated wells.
e ND, not determined. f Human sample 6 was previously reported by another laboratory to be positive for anti-p24 antibody in an immunoblot test.
only one site of an antibody to bind to the solid-phase antigen. Thus, we first had to determine the optimal conditions for coating the microplate wells with p40 antigen. This process was done essentially as described in a previous study (18) . To disperse the antigen, we used relatively large amounts of an unrelated protein (BSA, 20 g/ml) as a carrier protein and a high-ionic-strength condition (0.5 M NaCl) to lessen the protein-protein interaction. Under these conditions, we determined the optimal concentrations for coating p40 (200 ng/ml) and biotinylated p40 (2 g/ml) by checkerboard titration with BDV-infected rat serum.
Nonspecific binding of the antibodies to the well surface, if any, will not result in reaction signals in RS-ELISA because labeled antigens no longer bind to such antibodies. Thus, test samples with low dilutions can be used for this assay.
The addition of E. coli lysate is another crucial point in our assay. Bacterial proteins contaminating the p40 antigen solution on a solid phase could permit specific binding of antibodies to such proteins, followed by capturing of labeled bacterial proteins that were also included in the biotinylated p40 antigen solution, resulting in a positive ELISA reaction. To prevent this, a binding site of an antibody to bacterial proteins in the liquid phase must be blocked by nonlabeled proteins in E. coli lysates. By this step, the positive signal due to antibodies to bacterial proteins should be completely removed in this assay.
We used this RS-ELISA to detect anti-p40 antibodies in BDV-infected rat and rabbit sera (Fig. 3) . No background signal was seen in the control wells for all samples. All samples gave positive signals in the p40 antigen-coated control wells, albeit to different extents, indicating that the RS-ELISA was more sensitive than the indirect ELISA.
Detection of antibodies to BDV p40 in human specimens by RS-ELISA. We investigated the presence of anti-BDV antibodies using the same plasma samples that we used in our RS-ELISA described above. The specimens were diluted to 1:20 (10 times lower than the dilution used for the indirect ELISA) and were reacted in duplicate with either p40 or control antigen. All samples showed very low background signals, less than 0.014 of the ODs in the control wells, indicating that nonspecific attachment of biotinylated p40 did not occur. For samples from either the patients or the healthy individuals there were no considerable differences in the values between the p40 antigen-and control antigen-coated wells (Fig. 4A) , indicating that none of them contained anti-BDV p40 antibodies.
For a control experiment, we tested the same samples by RS-ELISA without the addition of E. coli lysate (Fig. 4B) . Some of them showed positive signals, demonstrating the presence of anti-bacterial protein antibodies as contaminants in the antigen solution. No significant difference in the percentages of positive signals was observed between the patients and the healthy subjects.
We next examined by our RS-ELISA additional human sera which had previously been judged to be seropositive for BDV by immunofluorescence or immunoblot test in other laboratories. Again, none of these samples showed any positive reaction signals (Table 1) . FIG. 3 . Detection of antibodies to BDV p40 in sera from a BDV-infected rat and rabbits. The sera were serially diluted and used to measure antibodies to BDV p40 in the RS-ELISA. All sera showed background signals with ODs of less than 0.03 in control antigen-coated wells even at the lowest dilution (1:1,600 for rat serum or 1:20 for rabbit sera). Closed circles, reaction data for rat serum in the RS-ELISA to which was added nonlabeled p40 antigen solution (2 g/ml) instead of labeled p40 as a control experiment to confirm the reaction specificity of the assay (rat control). Fig. 2 were examined. The difference in the OD at 650 nm and that at 450 nm (OD 450-650 ) for the p40 antigen-and control antigencoated wells was plotted for each test sample. Control wells for all samples showed very low background signals (less than 0.014). (B) The same samples were examined by RS-ELISA without the addition of E. coli lysates to detect antibodies to bacterial proteins that were contaminants in the p40 antigen solution. All samples in control wells showed low background signals (less than 0.014). When the cutoff value was set at an OD of 0.05, 2 of 70 (2.9%) serum samples from patients and 1 of 40 (2.5%) serum samples from healthy individuals showed positive signals. No significant difference was found between the two groups.
DISCUSSION
Previous seroepidemiological studies have suggested a possible association between BDV infection and human neuropsychiatric diseases (1, 2, 4, 10, 13, 14, 23-25, 29) . However, there has been a lack of consensus on a reliable serological method. The methods used in those studies, such as immunofluorescence assays (1, 2, 4, 23, 24) , immunoblot assays (10, 13, 14, 25, 29) , and indirect ELISAs (13) , are based on the use of labeled secondary antibody. In those assays, all the antibodies that bind to BDV antigens either specifically or nonspecifically could give a positive reaction. Therefore, it is difficult for the assay types to specifically detect anti-BDV antibodies at low concentrations in sera without false signals caused by nonspecific reactions. In this study, we evaluated an RS-ELISA for the detection of specific antibodies to BDV. The specificity of RS-ELISA is theoretically high because nonspecific binding of antibodies to the well surface should not be detected in this assay. Additionally, RS-ELISA can detect specific antibodies not only of all immunoglobulin classes but also from any variety of animal species under the same protocols because there is no requirement for class-or animal-specific secondary antibodies. Anti-allergen antibodies at low concentrations in sera were specifically detected by this strategy (18) .
Regarding the reaction specificity of the serological methods, an immunoblot assay in which the interaction between each BDV protein and antibodies can be directly detected should be more reliable than an immunofluorescence assay. In the immunoblot assay, the use of the crude antigens comprising BDV as well as cell proteins may be more preferable to the use of purified BDV antigens because a specific interaction between BDV protein and antibodies can be selectively detected. In an immunoblot assay with insect cell lysates infected with recombinant baculoviruses harboring BDV proteins, 9.6% of 416 neuropsychiatric patients and 1.4% of 203 healthy subjects contained anti-BDV antibodies (25) . Nonetheless, the possibility of a nonspecific interaction between a large amount of BDV proteins and antibodies in sera at a low dilution on the blotting membrane could not be ruled out in this assay. Additionally, indirect ELISAs with bacterium-expressed BDV proteins have been reported for the detection of BDV antibodies (6, 13) . One of the systems was demonstrated to have a high reaction specificity and a higher sensitivity than immunofluorescence, immunoblot, and immunoprecipitation tests with a series of BDV-infected rat sera obtained after experimental infection (6) . However, it is unknown whether this system can be applied to human specimens.
Here we established an RS-ELISA using bacterium-expressed recombinant p40 as an antigen for the detection of anti-BDV antibodies in serum. BDV p24 and gp18 proteins were also reported to be immunogenic, and specific antibodies to these proteins were detected in infected animals (12, 15, 21) . We tried to establish another RS-ELISA using p24 antigen. Thus, we used two p24 genes from different sources for the expression in bacteria; one was cloned from BDV-infected MDCK cells (kindly provided by R. Rott) through reverse transcriptase PCR procedures and the other one was from the previously cloned p24 plasmid (clone P4) (20) . Unlike p40, degradation of both p24 antigens was observed in our bacterium expression system, in contrast to the previous findings (6). When we used this degraded p24 antigen for RS-ELISA, BDV-infected rat serum showed a low antibody titer compared with the titer of the p40 antigen (if we set an OD of 0.1 as the cutoff value, the titer was 1:200 for p24 antigen, whereas it was 1:51,200 for p40 antigen). Since the antigenicity of this p24 antigen appeared to be altered, we decided not to use this p24 antigen for our RS-ELISA. Establishment of an RS-ELISA with gp18 is in progress.
In this study, our RS-ELISA did not detect any specific antibodies to BDV p40 in human samples, suggesting no association between BDV and psychiatric diseases in our test population. The sera that had been judged to be seropositive for BDV by the traditional methods were also negative by this assay. These findings raised two possibilities: (i) some positive results by previous studies may be false due to nonspecific reactions, or (ii) our RS-ELISA could not detect BDV-specific antibodies in human samples.
To clarify these possibilities, we compared the data obtained by indirect ELISA with those obtained by the RS-ELISA. The indirect ELISA indicated a possible association between BDV and neuropsychiatric disease. If the cutoff value was set at an OD of 0.1, 15 of 70 (21.4%) patients and 0 of 40 (0%) healthy individuals were positive for anti-BDV antibodies, resulting in a significant difference between the two groups (P Ͻ 0.005). By contrast, the same samples did not show any positive reaction with p40 in the RS-ELISA. One explanation for this discrepancy is that if antibodies are prone to bind to BDV p40 nonspecifically and such antibodies (or some factors causing this phenomenon) are present more frequently in samples from patients than in samples from healthy individuals, more positive signals would be observed in the indirect ELISA for samples from patients. On the other hand, these antibodies would not be detected in the RS-ELISA because the nonspecific binding of such antibodies should occur at both sites of the molecule. Unknown factors causing the nonspecific reaction are more likely to exist in sera from neuropsychiatric patients than in sera from healthy subjects.
Interestingly, all human samples showed very low signals in control wells in the RS-ELISA, regardless of the addition of E. coli lysates, although anti-bacterial protein antibodies were demonstrated (Fig. 4B) . These findings indicated that the concentrations of contaminating bacterial proteins were different between the p40 and control antigens or that these antigens contained different molecules of the bacterial proteins. If so, a precise background signal for the ELISAs cannot be determined for the control antigen prepared in this study. Additionally, no significant difference in detection of anti-bacterial protein antibodies between samples from patients and healthy subject (Fig. 4B) indicates that the presence of such antibodies did not affect the results of the indirect ELISA. Considering these observations, nonspecific binding of antibodies to p40 or bacterial proteins may give a misleading result in the indirect ELISA.
Conversely, the possibility that our RS-ELISA cannot detect anti-BDV antibodies in human samples should be considered. Although false-positive signals due to nonspecific binding of antibodies on the solid phase can be eliminated in the RS-ELISA, such antibodies may interfere with the specific binding of anti-p40 antibodies at a low concentration in the liquid phase, resulting in a negative reaction. RS-ELISA was able to detect low concentrations of specific antibodies from BDVinfected rat or rabbit sera (Fig. 3) . Additionally, it was able to detect possibly low concentrations of specific antibodies to bacterial protein contaminants in the p40 antigen solution (Fig. 4B ). These observations may rule out the possibility that a nonspecific reaction affected the specific reaction between p40 antigen and anti-p40 antibody in the RS-ELISA.
Alternatively, specific antibodies that were once bound to p40 antigen on the solid phase at one of the binding sites were possibly removed by the large number of washing steps in the RS-ELISA. If human BDV p40 has different, but cross-reactive, antigenicity from that of horse p40, the binding avidity between the horse antigen and human antibody would be weak. However, if the binding occurred at two sites of the antibody in the case of the indirect ELISA, antibodies could remain attached after washing, resulting in a positive signal. This may explain the different reaction profiles between the patients and the healthy individuals in the indirect ELISA.
Recently, the isolation of BDV from psychiatric patients (3) as well as the detection of viral antigens and RNA in autopsied brain samples from psychiatric patients (9) demonstrated BDV infection in humans. However, interpretation of BDV infection as a causative factor for neuropsychiatric disease is still controversial. Detection of BDV RNA fragments in PBMCs by reverse transcriptase PCR may be a powerful tool for determination of the epidemiology of BDV infection. A limited number of epidemiological studies by this strategy have detected viral RNA to a significantly larger extent in patients than in healthy controls. However, one study noted inconsistent findings by geographically different laboratories for the detection of BDV by reverse transcriptase PCR with the same test samples (25) . To elucidate an association of BDV infection to human neuropsychiatric diseases, it is crucial to establish reliable reverse transcriptase PCR systems with strict procedures to check for cross-contamination of samples due to extremely high sensitivity. RS-ELISA with human BDV antigens could also be a useful tool for determination of the seroepidemiology of BDV.
In conclusion, by our RS-ELISA we found no evidence of BDV infection in schizophrenic patients. Discrepancies in evaluations for BDV serology by different assays casts some doubts on previous seroepidemiological studies that have suggested an association between the BDV and several neuropsychiatric diseases.
